Difference between revisions of "SEIZURES-PHENYTOIN"
(Imported from text file) |
(Imported from text file) |
||
Line 2: | Line 2: | ||
1. Effective and well-tried, but no longer 1st line for generalized or partial epilepsy. | 1. Effective and well-tried, but no longer 1st line for generalized or partial epilepsy. | ||
<br/> | <br/> | ||
<br/>2. Toxicity | <br/>2. Toxicity: nystagmus, diplopia, tremor, dysarthria, ataxia. | ||
<br/> | <br/> | ||
<br/>3. SEs | <br/>3. SEs: decreased intellect, depression, coarse facial features, acne, gum hypertrophy, polyneuropathy, blood dyscrasias. | ||
<br/> | <br/> | ||
<br/>4. Increased clearance - OCP use, pregnancy. | <br/>4. Increased clearance - OCP use, pregnancy. |
Revision as of 11:07, 20 March 2023
SUMMARY
1. Effective and well-tried, but no longer 1st line for generalized or partial epilepsy.
2. Toxicity: nystagmus, diplopia, tremor, dysarthria, ataxia.
3. SEs: decreased intellect, depression, coarse facial features, acne, gum hypertrophy, polyneuropathy, blood dyscrasias.
4. Increased clearance - OCP use, pregnancy.
Reference(s)
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].